A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer

BACKGROUND: Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease with different subtypes, multidisciplinary teams-led management, and a poor prognosis. Currently, the clinical benefits of stage III NSCLC in the neoadjuvant setting are still unclear. We performed a meta-analysis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei, Zhang, Tiantian, Zhang, Qian, Li, Li, Xu, Chunhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798701/
https://www.ncbi.nlm.nih.gov/pubmed/36582007
http://dx.doi.org/10.1186/s12890-022-02292-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798701/
https://www.ncbi.nlm.nih.gov/pubmed/36582007
http://dx.doi.org/10.1186/s12890-022-02292-5

Ejemplares similares